Want to see IN:EPIGRAL full AI Analyst Report?
EPIGRAL Stock Chart & Stats
₹1244.30
-₹4.30(-0.24%)
At close: 4:00 PM EST
₹1244.30
-₹4.30(-0.24%)
Day’s Range― - ―
52-Week Range₹806.20 - ₹2,114.30
Previous CloseN/A
Volume42.70K
Average Volume (3M)1.86K
Market Cap
₹44.87B
Enterprise Value₹54.46B
Total Cash (Recent Filing)₹485.70M
Total Debt (Recent Filing)₹5.37B
Price to Earnings (P/E)13.5
Beta1.54
Next Earnings
Aug 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.46%
Share Statistics
EPS (TTM)93.51
Shares Outstanding43,141,340
10 Day Avg. Volume1,295
30 Day Avg. Volume1,859
Financial Highlights & Ratios
PEG Ratio-1.15
Price to Book (P/B)1.57
Price to Sales (P/S)1.40
P/FCF Ratio-535.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)93.8
Revenue Forecast (FY)₹33.92B
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthLeverage reduced to ~0.26x equity and expanded equity materially improve financial resilience. Lower debt cuts refinancing risk and interest burden, giving the company durable capacity to fund capex, withstand commodity cycles, and preserve strategic optionality over the next several quarters.
Sustainable Operating MarginsOperating and net margins near mid-teens reflect structural profitability for a chemicals firm, implying pricing power or cost efficiency. Such margin durability supports cash generation potential and return on equity through cycles, even if revenue growth pauses intermittently.
Long-term Revenue Growth Track RecordA history of multi-year revenue expansion suggests the company has market penetration, customer relationships, or product capabilities that can drive future growth when conditions normalize. This structural growth capacity underpins medium-term recovery potential.
Bears Say
Weak Cash GenerationNegative free cash flow and poor cash conversion are durable operational concerns: they constrain self-funding of capex, working capital, and distributions, and increase reliance on external financing. Over months this limits strategic flexibility and raises execution risk.
Earnings And Margin CompressionMaterial margin compression and flat sales versus the prior year signal weakening internal efficiency or pricing pressure. Persisting lower margins reduce reinvestable cash and long-run ROE, making it harder to sustain returns or finance growth without improving operational performance.
Recent Steep Top-line And EPS DeclinesVery large recent negative revenue and EPS growth indicate structural demand swings, lost volume, or one-off impairments that materially weaken near-term earnings capacity. Such trends raise the risk that profitability and cash generation remain depressed for multiple quarters.
Epigral Ltd News
EPIGRAL FAQ
What was Epigral Ltd’s price range in the past 12 months?
Epigral Ltd lowest stock price was ₹806.20 and its highest was ₹2114.30 in the past 12 months.
What is Epigral Ltd’s market cap?
Epigral Ltd’s market cap is ₹44.87B.
When is Epigral Ltd’s upcoming earnings report date?
Epigral Ltd’s upcoming earnings report date is Aug 03, 2026 which is in 30 days.
How were Epigral Ltd’s earnings last quarter?
Epigral Ltd released its earnings results on May 02, 2026. The company reported ₹19 earnings per share for the quarter, beating the consensus estimate of ₹14.3 by ₹4.7.
Is Epigral Ltd overvalued?
According to Wall Street analysts Epigral Ltd’s price is currently Overvalued.
Does Epigral Ltd pay dividends?
Epigral Ltd pays a Semiannually dividend of ₹5 which represents an annual dividend yield of 0.46%. See more information on Epigral Ltd dividends here
What is Epigral Ltd’s EPS estimate?
Epigral Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Epigral Ltd have?
Epigral Ltd has 43,141,340 shares outstanding.
What happened to Epigral Ltd’s price movement after its last earnings report?
Epigral Ltd reported an EPS of ₹19 in its last earnings report, beating expectations of ₹14.3. Following the earnings report the stock price went up 0.894%.
Which hedge fund is a major shareholder of Epigral Ltd?
Currently, no hedge funds are holding shares in IN:EPIGRAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Epigral Ltd
Epigral Limited operates in the chemical sector, focusing on the production and global distribution of chlor-alkali products and their associated derivatives. Its diverse product range encompasses chlorinated polyvinyl chloride (CPVC) resins, epichlorohydrin, chloromethanes, hydrogen peroxide, caustic soda, chlorine, hydrogen, and caustic potash. Additionally, the company is involved in the trading of agrochemical products. Epigral caters to an extensive list of industries, including CPVC pipes and fittings, wind energy, construction, paints and coatings, electronics, water treatment, agrochemicals, pharmaceuticals, refineries, soaps and detergents, fluoropolymers, paper and pulp, textiles, alumina, polyurethane foam, lithium, and polytetrafluoroethylene (PTFE) pipes. Incorporated in 2007 and based in Ahmedabad, India, the company was formerly known as Meghmani Finechem Limited until it adopted the name Epigral Limited in August 2023.
Technical Analysis
Gufic Biosciences Limited
―
Marksans Pharma Limited
―
Shilpa Medicare Limited
―
Strides Pharma Science Ltd
―
Supriya Lifescience Limited
―